Solana

Solana P/TBV

The Price to Tangible Book Value (P/TBV) of Solana (HSDT) as of Nov 4, 2026 is 0.30. In the previous year, Price to Tangible Book Value (P/TBV) was 86.19 — a change of -99.65% (lower).

P/TBV

0.30

YoY

-99.65%

Last updated:

Price to Tangible Book Value (P/TBV) of Solana is 2025 0.30 . Price to Tangible Book Value (P/TBV) of Solana was 2024 86.19 . It decreases by -99.65% lower compared to the previous year.

The Solana P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2018
9.26 USD
Jan 1, 2019
22.75 USD
Jan 1, 2020
35.35 USD
Jan 1, 2021
8.98 USD
Jan 1, 2022
11.39 USD
Jan 1, 2023
39.24 USD
Jan 1, 2024
86.19 USD
Jan 1, 2025
0.30 USD
The Solana P/TBV history
YEARP/TBVYoY
0.30-99.65%
86.19+119.64%
39.24+244.41%
11.39+26.86%
8.98-74.59%
35.35+55.42%
22.75+145.55%
9.26-176.01%
-12.19-99.78%
-5,636.76-0.01%
-5,637.11+9,552.30%
-58.40—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Solana Stock analysis

What does Solana do? Helius Medical Technologies develops and markets the PoNS device, a portable neuromodulation stimulator for neurological wellness. The company focuses on non-invasive platform technologies that enhance the brain's healing ability. The PoNS device is authorized as a class II medical device in Canada for short-term treatment of chronic balance deficits caused by mild-to-moderate traumatic brain injury, used alongside physical therapy. It delivers non-invasive neurostimulation to the tongue to induce neuromodulation. Helius Medical Technologies targets healthcare providers and rehabilitation centers that treat patients with traumatic brain injury. The company's product is designed for use in clinical settings under professional guidance, specifically for patients requiring short-term balance deficit therapy. The PoNS device is positioned as a complementary treatment within physical therapy protocols for neurological rehabilitation. The firm's revenue model is based on the sale of the PoNS device to healthcare institutions and rehabilitation facilities. These institutions purchase the device for use in their treatment programs, leveraging its non-invasive neurostimulation technology to address balance deficits in patients with mild-to-moderate traumatic brain injury. The company's focus on neurological wellness through non-invasive solutions drives its commercial strategy. Solana is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Solana stock

Price to Tangible Book Value (P/TBV) of Solana is 0.30 in 2025.

Price to Tangible Book Value (P/TBV) of Solana changed from 86.19 to 0.30, representing a -99.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Solana since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Solana with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Solana

All Key Metrics — Solana